Flag of the European Union EU Clinical Trials Register Help

Clinical trials for IGF-1

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    166 result(s) found for: IGF-1. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2009-012089-30 Sponsor Protocol Number: UZB-PED-2009-001 Start Date*: 2010-03-19
    Sponsor Name:UZ Brussel
    Full Title: Frequency and mechanisms of resistance to IGF-1 generation in non-GH deficient short children with low IGF-1 concentration
    Medical condition: Prepubertal children with stature < -2 SDS, IGF-1 < the lowest reference limit and normal growth hormone response to an ITT or glucagon test
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040600 Short stature LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001095-11 Sponsor Protocol Number: MS308 Start Date*: 2019-05-31
    Sponsor Name:Ipsen Pharma
    Full Title: RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF SHORT STATURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: A MULTICENTER, OPEN-LABEL, CONCENTRATION-CONTROLLED TRIAL
    Medical condition: Children with growth failure associated with primary insulin-like growth factor deficiency (IGFD).
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-001020-36 Sponsor Protocol Number: MS301 Start Date*: 2019-05-31
    Sponsor Name:Ipsen Pharma
    Full Title: RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF PREPUBERTAL CHILDREN WITH GROWTH FAILURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: A PHASE 3, RANDOMIZED, OPEN LABEL, OBSERVATI...
    Medical condition: Children with growth failure associated with primary insulin-like growth factor deficiency (IGFD).
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003183-31 Sponsor Protocol Number: DSC/13/2984/05 Start Date*: 2014-02-25
    Sponsor Name:ITALFARMACO S.p.A.
    Full Title: A Randomized, Multicenter, Phase II study to Investigate Efficacy and Safety of ITF2984 in Acromegalic patients.
    Medical condition: Acromegaly
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) NL (Completed) HU (Completed) ES (Completed) RO (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-000843-29 Sponsor Protocol Number: MS316 Start Date*: 2019-05-31
    Sponsor Name:Ipsen Pharma
    Full Title: Recombinant Human Growth Hormone (rhGH) and Recombinant Human Insulin-like Growth Factor-1 (rhIGF-1) Combination Therapy in Children with Short Stature Associated with IGF-1 Deficiency: A Six-year,...
    Medical condition: Idiopatic Short Stature in prepubertal children associated with low IGF-1 and normal stimulated GH response
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-002912-10 Sponsor Protocol Number: CH-ACM-01 Start Date*: 2011-08-31
    Sponsor Name:Chiasma, Inc.
    Full Title: EFFICACY AND SAFETY OF ORAL OCTREOLIN™ IN PATIENTS WITH ACROMEGALY WHO ARE CURRENTLY RECEIVING PARENTERAL SOMATOSTATIN ANALOGS
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    16.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed) GB (Completed) DE (Completed) SK (Completed) PL (Completed) IT (Completed) SI (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002630-31 Sponsor Protocol Number: CSOM230C2413 Start Date*: 2015-03-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase IIIb multicenter, open-label, single arm study to evaluate the efficacy and safety of pasireotide in patients with acromegaly inadequately controlled with first generation somatostatin ana...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    19.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) PT (Completed) IT (Completed) FR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-000844-81 Sponsor Protocol Number: MS306 Start Date*: 2019-05-31
    Sponsor Name:Ipsen Pharma
    Full Title: RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF CHILDREN AND ADOLESCENTS WITH GROWTH FAILURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: AN OPEN-LABEL, MULTI-CENTER, EXTENSION S...
    Medical condition: Children and adolescents with growth failure associated with primary insulin-like growth factor deficiency (IGFD).
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-001315-22 Sponsor Protocol Number: GH003 Start Date*: 2006-03-09
    Sponsor Name:Ludwig Boltzmann Gesellschaft
    Full Title: The effect of the cholinesterase inhibitor donepezil on organic and functional deficits related to growth hormone deficiency in old age.
    Medical condition: We plan to study healthy aging subjects.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000675-20 Sponsor Protocol Number: ISIS766720-CS5 Start Date*: 2020-11-04
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: An Open Label, Randomized, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor, Administered Monthly as Monotherap...
    Medical condition: Acromegaly is a chronic disorder caused by GH hypersecretion, most commonly as a result of a GH-secreting pituitary adenoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) PL (Completed) LV (Prematurely Ended) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-000737-31 Sponsor Protocol Number: OOC-ACM-303 Start Date*: 2017-10-27
    Sponsor Name:Chiasma, Inc.
    Full Title: A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of octreotide capsules in patients who previously tolerated and demonstrated biochemical c...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) NL (Completed) SE (Completed) DK (Completed) PL (Completed) IT (Completed) BG (Completed) LV (Completed) SI (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-000297-72 Sponsor Protocol Number: 2-55-52030-727 Start Date*: 2007-04-24
    Sponsor Name:BEAUFOUR IPSEN Pharma
    Full Title: Phase III, multicentre, open study to assess the efficacy and safety profiles of the co-administration of lanreotide Autogel 120 mg (administered via deep subcutaneous injections every 28 days) and...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    8.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GR (Completed) DE (Completed) CZ (Completed) DK (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-004259-22 Sponsor Protocol Number: ISIS766720-CS2 Start Date*: 2018-06-05
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor) Administered...
    Medical condition: Acromegaly is a chronic disorder caused by GH hypersecretion, most commonly as a result of a GH-secreting pituitary adenoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) LT (Completed) CZ (Prematurely Ended) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-001145-11 Sponsor Protocol Number: TransCon_hGH_CT-301 Start Date*: 2018-02-12
    Sponsor Name:Ascendis Pharma Endocrinology Division A/S
    Full Title: A multicenter, Phase 3, randomized, open-label, active-controlled, parallel-group trial investigating the safety, tolerability, and efficacy of TransCon hGH administered once a week versus standard...
    Medical condition: Growth hormone deficiency (GHD) in prepubertal children
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) BG (Completed) PL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-005855-14 Sponsor Protocol Number: C2L-OCT-01 PR-301 Start Date*: 2007-02-22
    Sponsor Name:Ambrilia Biopharma Inc.
    Full Title: OPEN LABEL, RANDOMIZED STUDY COMPARING THE BIOLOGICAL EFFICACY AND SAFETY OF A NEW PROLONGED RELEASE FORMULATION OF OCTREOTIDE ACETATE, C2L-OCT-01 PR, 30 MG ADMINISTERED INTRA MUSCULARLY EVERY 42 D...
    Medical condition: Acromegaly
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002193-31 Sponsor Protocol Number: CRN00808-05 Start Date*: 2020-02-19
    Sponsor Name:Crinetics Pharmaceuticals, Inc.
    Full Title: AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRN00808 IN SUBJECTS WITH ACROMEGALY (ACROBAT ADVANCE)
    Medical condition: Acromegaly is typically caused by a growth hormone (GH) secreting tumor in the pituitary. Excess GH secretion results in excess secretion of insulin-like growth factor-1 (IGF-1) from the liver, whi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) SK (Completed) GR (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015739-34 Sponsor Protocol Number: FRA.GHAT.2009 Start Date*: 2009-12-09
    Sponsor Name:Goethe-Universität Frankfurt/Main
    Full Title: Status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and neuroprotection in children with Ataxia telangiectasia (AT)
    Medical condition: This study will evaluate the status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and composition and neuroprotection in children wi...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017011-16 Sponsor Protocol Number: 0000000000000000000 Start Date*: 2011-06-16
    Sponsor Name:University Federico II
    Full Title: Treatment of the low IGF-1 syndrome associated with Chronic Heart Failure: A Randomized, Placebo-Controlled, Double-Blind Study
    Medical condition: Low serum IGF-I and GH deficiency in patients with congestive heart failure
    Disease:
    Population Age: Adults, Elderly Gender:
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019296-30 Sponsor Protocol Number: Start Date*: 2010-05-18
    Sponsor Name:University Hospital Birmingham NHS Foundation Trust
    Full Title: A pharmacokinetic and pharmacodynamic study of recombinant human IGF-I (rhIGF-I) in three boys with ALS deficiency, and insulin sensitivity and bone density in patients and heterozygous first-degre...
    Medical condition: ALS (acid label subunit) deficiency
    Disease: Version SOC Term Classification Code Term Level
    12.1 10056438 Growth Hormone Deficiency LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001703-32 Sponsor Protocol Number: CRN00808-08 Start Date*: 2022-03-29
    Sponsor Name:Crinetics Pharmaceuticals, Inc.
    Full Title: A Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Non-pharmacologically Treated Acromegaly
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) GR (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 05:47:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA